Dynamic changes in circulating microRNAs during oral glucose tolerance testing support their potential as diagnostic and monitoring biomarkers in cystic fibrosis-related diabetes
Authors' conclusion
MiR-34a-5p and miR-122-5p show potential as biomarkers for CFRD development and liver damage. MiR-122-5p and miR-223-3p could mitigate CFRD development by increasing the secretory capacity of the beta cells while miR-34a-5p might propagate CFRD development by reducing cell viability. We propose that circulating microRNAs can serve as biomarkers for CF complications. We further advocate that circulating microRNAs can play a part in the intricate crosstalk between metabolic organs and the endocrine pancreas in health and disease.
Study context
- Population
- Adult Danish participants with cystic fibrosis12 sequenced
- Participants
- 93 participants
- Exposure
- Circulating microRNAs across glucose tolerance categories in cystic fibrosis (CF)
- Outcome
- Serum microRNA expression by glucose tolerance status and during OGTT
Methodological detailsOGTT sampling at baseline, 10, 30, 60 and 180 min, serum microRNA sequencing in 12 selected individuals, LNA RT-qPCR validation in full cohort, in vitro assessment in insulin-secreting cells
- OGTT sampling at baseline, 10, 30, 60 and 180 min
- Serum microRNA sequencing in 12 selected individuals
- LNA RT-qPCR validation in full cohort
- In vitro assessment in insulin-secreting cells
Main finding
As reported in the abstract
MicroRNAs differentially expressed at baseline (miR-34a-5p, miR-122-5p, miR-885-3, miR-885-5p)
4
MicroRNAs with differential expression changes in response to glucose ingestion
12
MicroRNAs validated by LNA RT-qPCR
8
Observational data: associations, not effects.
Further findings
In vitro effects in insulin-secreting cells
- Glucose-stimulated insulin secretion increased after overexpression of miR-122-5p or miR-223-3p
- Cell viability decreased after overexpression of miR-34a-5p
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →